Introduction
Lung transplantation has become an accepted intervention for patients with advanced lung disease. 1 Long-term survival for lung recipients is limited mainly by opportunistic infections and chronic rejection. Acute cellular rejection has been identified as the primary risk factor for chronic organ dysfunction/bronchiolitis obliterans syndrome (BOS). 2e5 It has been graded according to histopathological changes. 6e8 Studies examining the impact of acute rejection on BOS have established a strong association between high-grade acute rejection (!A2), recurrent episodes of acute rejection, a cumulative burden of acute rejection and episodes of late acute rejection with BOS.
9e11 Even a single episode of minimal acute rejection (grade A1) without recurrence or subsequent progression to a higher grade is a risk factor significant for BOS and requires therapy. 12, 13 Symptomatic and high-grade AR (!A2) should be promptly treated with intravenous steroid pulse therapy along with adoption of the immunosuppressive regimen. Steroid-resistant AR may be treated by anti-lymphocyte globulins or may reflect an alternative underlying process.
Transbronchial lung biopsy is currently the most sensitive and specific test for lung rejection and allows the differentiation from infection. However, it is an invasive procedure requiring bronchoscopy, which is not always tolerated well by patients and carries obvious limitations as a tool for repeat testing.
14 Previous studies using a combined approach with bronchoalveolar lavage fluid (BALF, to exclude infection) and transbronchial lung biopsy (TBB) have reported that the sensitivity for the detection of AR ranges from 60% to 75% in recipients of heartelung (HLT) and bilateral-lung (BLT) transplantation 15, 16 and from 48% to 72% in recipients of single-lung transplantation. 17 Daily home spirometry with a portable spirometer is advocated in the follow-up of lung transplant recipients by some centres and may detect changes in graft function related to rejection earlier. The aim of this study was to investigate the value of different markers, e.g. lung function, home spirometry, bronchoalveolar lavage fluid (BALF) and blood samples (white blood cells (WBC), C-reactive protein, arterial blood gases) on steroid sensitivity in acute graft rejection.
Methods

Study design
A prospective cohort study was performed in lung and heartelung transplant recipients who were followed in the outpatient clinic of Hannover Medical School from Jan. 2005 until Nov. 2007. We analysed 85 patients with symptomatic biopsy proven acute rejection (AR) prospectively.
Patients were qualified for the study if they were at least 6-month post-transplant, had biopsy proven AR, decline in lung function (!10% in FEV 1 comparing to FEV 1 during previous visit) with clinical symptoms. Patients were at previous outpatient clinic visit in stable functional situation (FEV 1 ! 90% of best-FEV 1 ). Surveillance biopsies were not standard of our program during the study period. Patients with pulmonary infections, established BOS and other reasons for decline in graft function were excluded. In-/exclusion criteria and baseline characteristics are shown in Tables 1 and 2 .
Primary endpoint of this study was steroid response in acute allograft rejection; secondary endpoint included restitution in biopsy A grade and onset BOS.
Steroid response was defined as increase in FEV 1 of at least 10% after steroid pulse therapy compared to FEV 1 at rejection date (date of study inclusion). The therapeutic success of steroid pulse therapy was evaluated at least 14 days after steroid pulse therapy. Patients were divided into group 1: steroid-sensitive AR, and group 2: steroid-resistant AR. Control biopsy for histopathological response was not standard of our program. In steroid non-responders Prior to enrollment, the project had been approved by the Institutional Review Board. All subjects gave written informed consent before their participation in the program and the study was approved by the local ethics committee. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement was used as a guideline for reporting the study results. 22 
Standard of care
Standard maintenance immunosuppression consisted of a triple drug regimen, including a calcineurin inhibitor, prednisolone, and a mycophenolate mofetil or an mTOR (mammalian target of rapamycin)-inhibitor. Patients with recurrent or steroid-resistant episodes of rejection were switched from cyclosporine to tacrolimus. Tacrolimus was used as the primary calcineurin inhibitor in patients after HLTx. In target trough level was defined as desired trough level AE10%.
AR was treated with adoption of immunosuppressive therapy where necessary, using intravenous methylprednisolone 15 mg/kg/day for 3 days. Based on histological severity of findings, presence of associated symptoms and prior biopsy grades, the maintenance immunosuppressive regimen was suitably modified.
Bronchoscopy
Bronchoscopy was performed in patients with new respiratory symptoms (i.e. dyspnoea, cough), signs (i.e. fever, crackles), infiltrates on chest X-ray, and/or declining lung function (i.e. decrease of FEV 1 of !10% compared to previous outpatient clinical visit).
Transbronchial lung biopsies were obtained from the lung periphery with 2 or 2.5 mm fenestrated forceps (FB-231D, Olympus, Hamburg, Germany) without routine fluoroscopic guidance. Five biopsies from one lung, two lobes (sparing middle-lobe and lingula) and at least three segments were targeted. Following all biopsies, a chest X-ray was performed after 1e2 h to exclude any possible pneumothoraces.
The severity of acute rejection was graded according to the criteria of the International Society for Heart and Lung Transplantation (ISHLT).
6e8 Specimens with less than 50 alveoli were graded as AX and did not comply with the inclusion criteria.
Definitions of infection
Bacterial infection was given when any pulmonary pathogen was cultured with a bacterial load of more than 10 4 cfu/ml. Infection with community acquired respiratory viruses (CARV) were defined as any positive results in direct virus isolation (cultures), antigen testing or viral culture for, Influenzavirus A and B, Parainfluenzavirus I-III, RSV and Adenovirus. Fungal infection was defined as ''proven'' or ''probable according to the EORTC/MSG consensus group criteria. 23 CMV infection was defined as direct CMV virus isolation or detection of viral proteins or nucleic acid in any body fluid or tissue specimen. 24 CMV antigen was routinely measured in LTx recipients. Significant antigenemia was defined as more than 3/400,000 positive CMV-pp65 leucocytes with initiation of antiviral therapy or adaptation of immunosuppressive regimen.
Pulmonary function tests
Spirometry was performed according to ATS/ERS guidelines. 25 BOS staging was defined as a FEV 1 < 80% best after transplantation according to the International Society of Heart and Lung Transplantation (ISHLT) system. 26 Best-FEV 1 was defined as the average of the two highest measurements obtained at least 3 weeks apart during the postoperative course. Home spirometry was recommended to all recipients to be performed once daily (three expiratory flow-volume parameters) and stored in a recording device (AM1, Viasys Healthcare, Hochberg, Germany). Home spirometry adherence was defined as measurements in percentage of recommended measurements (max. 100%). The subjects were instructed to contact their transplant coordinator if they observed declining FEV 1 , or developed new signs or symptoms. Patients were instructed to contact their transplant centre immediately if a >10% decline in home spirometry occurred.
Statistics
Data are reported as means (AEstandard deviation), time dependent variables are expressed as median (minimum and maximum). All reported p-values are two-sided, unless otherwise indicated. For all analyses, p-values <0.05 were considered statistically significant.
For univariate analysis, categorical variables were analyzed by chi-squared test or Fisher's exact test. Medians were compared with the ManneWhitney test. Means were analyzed with Student's t-test. Multivariate analysis included logistic regression (for steroid response). All variables with a p-value <0.10 were included and variables with a p-value of >0.10 were excluded in a multivariate analysis.
Receiver operating curves (ROC) were constructed to show the correlation between predictors and steroid response. We constructed a scoring system for steroid response quantification (SRQ), using the clinically important variables or those independently related to steroid response. The correlation between SRQ and steroid response was evaluated with linear regression analysis. For all analyses, a p-value <0.05 was considered statistically significant. Statistical analysis was conducted using SPSS 15.0 (SPSS Inc., Chicago, IL).
Results
This study included 85 double lung-/heartelung transplanted patients. The distribution of histopathological findings of TBB and immunosuppressive regimens are shown in Tables 2 and 3 . Forty-seven patients had steroid-sensitive AR (group 1) with recovery of lung function, while 38 patients did not respond to steroid pulse therapy (group 2) despite biopsy proven AR. Eight patients (21%) of group 2 developed BOS during the following 6 months (Fig. 1) .
Immunosuppressant levels were analyzed retrospectively over 3 months before the date of biopsy proven rejection. There were 188 immunosuppressant levels measured in group 1 and 152 levels in group 2 (1.3 measured levels/month/patient in group 1, 1.4 measured levels/ month/patient in group 2). Immunosuppressant in target levels and history of rejection episodes was not significantly different between both groups (p Z 0.84, p Z 0.57). The immunosuppressive regimen was switched in 7/47 patients of group 1 (15%) once before, in 1/47 patient twice before the study period (2%). The immunosuppressive regimen during the postoperative period was changed in group 2 in 8/38 (22%) pts. once and in 1/38 (3%) patient three times (of total: 38) ( Table 4) .
We abstained from control biopsies in case of complete recovery of graft function (FEV 1 ! 100% compared to previous FEV 1 in outpatient clinic) in the absence of new clinical findings. In case of incomplete recovery of graft function, control biopsies were performed in 22/47 (49%) patients of group 1 and 21/38 (55%) patients in group 2 after median 42 days (14e 90). In group 1, two patients with A2 rejection stepped down to A1, in group 2 in 1 patient with A2 rejection changed to A1 rejection. All other biopsies turned to A0 (70%). From the eight patients developing BOS 6 months later, half of them received control biopsies within 3 month after rejection date. All of them turned from A1 to A0.
Univariate analysis showed ''days after transplantation'' (p Z 0.01), ''days between last follow up and rejection date'' (p Z 0.01), ''decline in FEV 1 slope'' (p Z 0.01), ''decline in home spirometry slope'' (p Z 0.02) and ''adherence home spirometry'' (0.01) as significant (Table 4) .
There was no significant difference between age, gender, underlying disease, type of transplantation, immunosuppressive regimen at time of rejection nor FEV 1 baseline (ml/s). Serum marker CRP (p Z 0.01) and BALF eosinophils (p Z 0.01) proved to be significant. Blood gas analysis and histological grading of rejection could not been identified as significant different (Table 4 ).
Multivariate analysis revealed that ''days after transplantation'' (p Z 0.01, adjusted hazard ratio (HR) 1.2), ''decline in home spirometry slope'' (p Z 0.03, HR 0.97), ''adherence home spirometry'' (p Z 0.05, HR 0.98) and ''serum CRP'' (p Z 0.02, HR 0.87) were independent risk factors. ''Decline in FEV 1 slope'' and ''home spirometry decline before contact'' did not reach statistical significance as independent risk factors. Overall, ''days after transplantation'' showed the highest significance (p Z 0.01) ( Table 5) .
Receiver operating curves (ROC) demonstrated the high prognostic value of ''days after transplantation (d)'' to predict steroid-sensitivity in acute graft rejection (Fig. 2) . Eighty-five percent of patients showed response to steroid pulse therapy in case of proven acute rejection during the first year after transplantation, if only 55% of patients did respond to steroids 2 years after transplantation. Fig. 3 demonstrates that SRQ related significantly to steroid response (p < 0.01), with total scores between 0 and 8, respectively, demonstrating 20%, 0%, 8%, 29%, 50%, 82%, 86%, and 100% likelihood of a steroid response (Table 6 , Fig. 3 ). 0  0  B0  5  3  A1  29  28  B1  20  13  A2  18  10  B2  12  12  A3  0  0  B3  0 Indicators for steroid response in biopsy
Discussion
Our data demonstrate a different clinical profile for patients with steroid sensitivity outside the first 6 postoperative months after LTx to those which exhibited no response to steroid therapy. Primarily we could show that time after Tx, more rapid decline and adherence to home spirometry and serum CRP are independent predictors for steroid sensitivity. Several earlier studies have shown the diagnostic value of home spirometry for graft dysfunction. 15, 18 In places where patients live at long-distances from their transplant centre diagnostic tools like home spirometry might be particularly helpful. Predictably, adherence to home spirometry appears to vary between individuals and may be monitored by home spirometry because it is a risk factor for negative clinical outcomes in relation to acute rejections, graft vasculopathy, higher costs, and mortality. 27 We could demonstrate that both adherence to home spirometry along with the pattern of decline (fast decline in home spirometry slope ml/d) are independent prognostic markers for steroid sensitivity in allograft rejection, and therefore could additionally influence the long-term outcome. Home spirometry decline before contact as another marker for adherence was shown (d) (p Z 0.01).
With serum marker CRP we could find another straightforward tool associated with low costs to be a significant marker of steroid sensitivity. Other markers like serum procalcitonin (PCT) need to be evaluated. Differences in BALF cell counts did not seem to be significant for risk stratification, although our data showed in univariate analysis BALF eosinophiles as significantly different (p Z 0.01). Nevertheless our analysis could not show that BALF eosinophiles are independent predictor for steroid response in multivariate analysis. Although increased eosinophils in BALF have been observed in allograft rejection, this relationship is less well defined. The role of eosinophils in the pathophysiology of allograft rejection is unclear. 28 Of particular concern is that only 55% of all patients had steroid-sensitive disease. There is still debate about the specificity of transbronchial biopsies in diagnosing acute rejection. Also, surveillance biopsies are not uniformly applied in the follow-up care of lung transplant recipients worldwide especially not after the early postoperative period. Complications may pose a greater risk than indication led to bronchoscopy. In this study, performing transbronchial indication biopsies in outpatient lungtransplant recipients proved to be safe. In addition, inter- Our data could show that patients of group 1 tend to be earlier in their postoperative course than patients in group 2 (296 vs. 1008 days post Tx, Table 4 ). The information that only 55% responded to steroid pulse therapy after the second postoperative year should be considered in future therapy regimens. Our results question the clinical importance of acute cellular rejection in pts. ''late'' after LTx. In lung transplant recipients more than 2 years after surgery with declining graft function and refractory to steroid pulse therapy, a further intensive work-up for BOS (CT scan, exclusion of gastroesophageal reflux, etc.) is warranted. Risks of transbronchial biopsy (bleeding, pneumothorax) should be weighed against the benefit of additional findings of biopsy (e.g. infection or malignancy).
Several studies have demonstrated that acute rejection can be present in asymptomatic lung transplant recipients in around 25% of patients monitored by surveillance biopsies, which might be a confounding mechanism influencing BOS. 32, 33 Histopathological findings in BOS patients is a poorly studied area. Martinu et al. reviewed in 12 patients' pathological findings in explanted allografts which underwent pulmonary re-transplantation for BOS. They Significance, specificity, negative predictive value (NPV) and positive predictive value (PPV) score for 5e8 points. described findings of acute cellular rejection with marked heterogeneity (A1e3) in 100% explanted lungs. This might contribute to the variability of patient responses to treatment. 34 In our study 21% in group 2 developed BOS during the following 6 months. Our findings of mild A-grade rejection also in patients with early BOS in next half year complement with Martinu et al. and underlines the variability of clinical findings in patients with OB/BOS after lung transplantation. That biopsy proven acute rejection occurring more than 2 years after transplantation is more likely to be steroid-resistant represents new information. To our knowledge, there is no prospective study which demonstrated this effect. Early recognition of deteriorating graft function by home spirometry may give clinicians a window of opportunity for earlier diagnosis and therapy in pts. with AR or onset of BOS.
We obtained 3.2 biopsy specimens in average per patient at outpatient bronchoscopy, lower than the recommended 5 specimens according to the current guidelines. 6 Signs of respiratory failure and significant bleeding (suction of >100 ml blood) limited in some cases to obtain the required number in the majority of patients with less than five biopsy specimen. Discussion continues regarding the implicit loss of diagnostic sensitivity in TBB series that report too few biopsies per procedure when attempting to compare contemporary studies. 35 Nevertheless, the incomplete number of biopsies in patients and the incomplete performance of control biopsies in group 2 after steroid pulse therapy are study limitation. Another study limitation is that we ruled out patients with any virus isolation but we did not detect for HHV6,7 or human metapneumovirus in this study, which can also be reasonable for graft dysfunction. 36 In conclusion this study shows that an acute rejection episode had a higher likelihood of responding to pulse steroid therapy in lung transplanted patients ''earlier'' after surgery with a sudden decrease in lung function over a short period, which demonstrated high adherence to home spirometry and exhibited an associated elevated serum CRP. Additionally, histopathological findings of mild A grades are losing their expressiveness with the time after transplantation. In case of incomplete clinical response to steroid pulse therapy patients should be intensively monitored for signs of BOS. 
